Advertisement

Pharmaceutical Chemistry Journal

, Volume 53, Issue 5, pp 383–387 | Cite as

Comparative Evaluation of Antiparkinsonian, Anti-Inflammatory, and Analgesic Effects of Hemantane and Two 2-Aminoadamantane Derivatives Differing From it by a Bridgehead Hydroxyl

  • I. G. Kapitsa
  • E. A. IvanovaEmail author
  • N. I. Avdyunina
  • T. A. Voronina
MOLECULAR-BIOLOGICAL PROBLEMS OF DRUG DESIGN AND MECHANISM OF DRUG ACTION
  • 3 Downloads

2-Adamantylaminopropanol hydrochloride (ADK-971) and 5-hydroxyadamantan-2-ylaminopropanol hydrochloride (ADK-1013) were less active than hemantane in parkinsonian syndrome murine models. ADK-971 and AKD-1013, like hemantane at a dose of 20 mg/kg, exhibited comparable antiexudative effects in the mouse acetic peritonitis model. However, ADK-971 and ADK-1013 (20 mg/kg), in contrast to hemantane at the same dose, did not possess analgesic effects against visceral and thermal somatic pain in mice.

Keywords

aminoadamantane parkinsonian syndrome inflammation acetic peritonitis pain 

Notes

Acknowledgments

The work was sponsored by a State Task on Topic No. 0521-2019-0007.

References

  1. 1.
    https://www.rlsnet.ru/mnn index id 2206.htm#primenenie-veshhestva-memantin
  2. 2.
  3. 3.
    A. V. Nepoklonov, I. G. Kapitsa, E. A. Ivanova, et al., Eksp. Klin. Farm., 75(11), 3 – 6 (2012).Google Scholar
  4. 4.
    E. A. Ivanova, A. V. Nepoklonov, I. I. Kokshenev, et al., Biomeditsina, 1(1), 74 – 81 (2012).Google Scholar
  5. 5.
    E. A. Ivanova, I. G. Kapitsa, E. A. Val’dman, and T. A. Voronina, Byull. Eksp. Biol. Med., 159(3), 362 – 365 (2015).CrossRefGoogle Scholar
  6. 6.
    E. A. Katunina, A. V. Petrukhova, G. N. Avakyan, et al., Zh. Nevrol. Psikhiatr. im. S. S. Korsakova, 108(6), 24 – 27 (2008).Google Scholar
  7. 7.
    E. A. Ivanova, I. G. Kapitsa, A. V. Nepoklonov, et al., Khim.- farm. Zh., 47(10), 12 – 15 (2013); Pharm. Chem. J., 47(10), 517 – 520 (2013).Google Scholar
  8. 8.
    E. A. Ivanova, I. G. Kapitsa, E. A. Valdman, and T. A. Voronina, Adv. Parkinson’s Dis., No. 5, 50 – 60 (2016).Google Scholar
  9. 9.
    I. G. Kapitsa, E. A. Ivanova, T. A. Voronina, et al., Farmakokinet. Farmakodin., No. 3, 42 – 46 (2016).Google Scholar
  10. 10.
    RU Pat. Appl. 4,947,575 / 04; Byull. Izobret., No. 4 (2011).Google Scholar
  11. 11.
    N. I. Avdyunina, I. S. Morozov, et al., RU Pat. 1,746,661, Jan. 10, 1996.Google Scholar
  12. 12.
    N. V. Klimova, B. M. Pyatin, N. M. Zaitseva, et al., Khim.-farm. Zh., 20(7), 810 – 915 (1986).Google Scholar
  13. 13.
    T. A. Voronina, E. A Val’dman, L. N. Nerobkova, and I. G. Kapitsa, Methodical Recommendations for Preclinical Trials of Antiparkinsonian Drugs [in Russian], in: Handbook for Preclinical Drug Trials [in Russian], Part 1, Grif i K, Moscow, 2012, pp. 219 – 234.Google Scholar
  14. 14.
    J. L. Tillerson and G. W. Miller, J. Neurosci. Methods, 123(2), 189 – 200 (2003).CrossRefGoogle Scholar
  15. 15.
    G. Ya. Shvarts and R. D. Syubaev, Methodical Recommendations for Preclinical Trials of Nonsteroidal Anti-Inflammatory Drugs [in Russian], in: Handbook for Preclinical Drug Trials [in Russian], Part 1, Grif i K, Moscow, 2012, pp. 746 – 758.Google Scholar
  16. 16.
    T. A. Voronina and L. S. Guzevatykh, Methodical Recommendations for Preclinical Trials of Analgesic Drugs [in Russian], in: Handbook for Preclinical Drug Trials [in Russian], Part 1, Grif i K, Moscow, 2012, pp. 197 – 218.Google Scholar
  17. 17.
    I. G. Kapitsa, I. I. Kokshenev, E. A. Val’dman, and T. A. Voronin, Farmakokinet. Farmakodin., No. 2, 10 – 16 (2012).Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • I. G. Kapitsa
    • 1
  • E. A. Ivanova
    • 1
    Email author
  • N. I. Avdyunina
    • 1
  • T. A. Voronina
    • 1
  1. 1.V. V. Zakusov Research Institute of Pharmacology, Russian Academy of Medical SciencesMoscowRussia

Personalised recommendations